Dynepo Appellate Decision Gives TKT Another Chance Against Amgen Patents
Executive Summary
Transkaryotic Therapies will have a second chance to argue that its gene activated-EPO product Dynepo does not violate patents for Amgen's erythropoietin product Epogen following a Jan. 6 decision by the D.C. federal appellate court